The market for anti-infective medicines in Australia has shown significant fluctuations over the past decade. From a steady rise in 2013, the market peaked dramatically in 2016 before experiencing a sharp decline in subsequent years. Despite an upward trend from 2022, with a value standing at $1300 million in 2023, yearly variation rates illustrate considerable volatility with notable declines particularly between 2018 and 2021. The forecast from 2024 onward suggests a modest 1.51% CAGR, indicating a slowing growth rate but a steady increase over the next five years.
Key historic trends:
- 2013-2016: Significant market expansion culminating in a 311.95% YoY increase in 2016.
- 2017-2021: Sustained decline marked by considerable year-on-year decreases, especially notable in 2018 and 2019.
- 2022-2023: Rebound with a 58.68% YoY increase in 2022, moderate growth of 6.05% in 2023.
Future trends to watch for:
- Potential impacts of new anti-infective drugs entering the market which could influence growth rates.
- The role of regulatory changes and health policies in affecting market dynamics.
- Evolving resistance to existing medications, driving demand for novel treatments.
